Search Results for: FGFR2

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
Novel ANOS1 anosmin 1
  • FGFR1c ligand binding and activation
  • Negative regulation of FGFR1 signaling
  • Hypogonadotropic hypogonadism; Kallmann syndrome (KAL)
Novel APP amyloid beta precursor protein
  • Platelet degranulation
  • ECM proteoglycans
  • Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
  • G alpha (q) signalling events
  • G alpha (i) signalling events
  • Lysosome Vesicle Biogenesis
  • Formyl peptide receptors bind formyl peptides and many other ligands
  • TAK1-dependent IKK and NF-kappa-B activation
  • The NLRP3 inflammasome
  • Advanced glycosylation endproduct receptor signaling
  • Advanced glycosylation endproduct receptor signaling
  • Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
  • Post-translational protein phosphorylation
  • TRAF6 mediated NF-kB activation
  • Insertion of tail-anchored proteins into the endoplasmic reticulum membrane
  • Insertion of tail-anchored proteins into the endoplasmic reticulum membrane
  • Purinergic signaling in leishmaniasis infection
  • Amyloid fiber formation
  • Deferoxamine
  • Aluminium
  • Zinc
  • L-methionine (R)-S-oxide
  • Resveratrol
  • Tromethamine
  • Phenserine
  • Tetrathiomolybdate
  • CAD106
  • Mito-4509
  • Edonerpic
  • Dimercaprol
  • Copper
  • Florbetaben (18F)
  • Florbetapir (18F)
  • Flutemetamol (18F)
  • Gantenerumab
  • Aducanumab
  • Zinc acetate
  • Aluminium phosphate
  • Aluminum acetate
  • Zinc chloride
  • Zinc sulfate, unspecified form
  • Lecanemab
  • Alzheimer's disease (AD)
Novel BEX1 brain expressed X-linked 1
Novel BEX2 brain expressed X-linked 2
Novel CACNA1D calcium voltage-gated channel subunit alpha1 D
  • Adrenaline,noradrenaline inhibits insulin secretion
  • NCAM1 interactions
  • Regulation of insulin secretion
  • Regulation of insulin secretion
  • Sensory processing of sound by inner hair cells of the cochlea
  • Ergocalciferol
  • Enflurane
  • Ranolazine
  • Phenytoin
  • Isradipine
  • Topiramate
  • Nimodipine
  • Nisoldipine
  • Spironolactone
  • Cinnarizine
  • Nicardipine
  • Nicardipine
  • Magnesium sulfate
  • Verapamil
  • Levomenthol
  • Ethanol
  • Felodipine
  • Nitrendipine
  • Nitrendipine
  • Miconazole
  • Nifedipine
  • Amiodarone
  • Mibefradil
  • Dronedarone
  • Clevidipine
  • Nilvadipine
  • Nilvadipine
  • Drotaverine
  • Trimebutine
  • Aranidipine
  • Benidipine
  • Cilnidipine
  • Efonidipine
  • Efonidipine
  • Lacidipine
  • Levamlodipine
  • Manidipine
  • Butamben
  • Bioallethrin
  • Bioallethrin
  • Fish oil
Novel CTDSP1 CTD small phosphatase 1
  • Aspartate beryllium trifluoride
  • Citric acid
Novel CTDSPL CTD small phosphatase like
Novel DUSP14 dual specificity phosphatase 14
Novel ELK4 ETS transcription factor ELK4
  • Prostate cancer
Novel EPHA4 EPH receptor A4
  • EPH-Ephrin signaling
  • EPH-Ephrin signaling
  • EPHA-mediated growth cone collapse
  • EPHA-mediated growth cone collapse
  • EPH-ephrin mediated repulsion of cells
  • EPH-ephrin mediated repulsion of cells
  • Somitogenesis
  • Fostamatinib
Novel ERBB2 erb-b2 receptor tyrosine kinase 2
  • Signaling by ERBB2
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • PLCG1 events in ERBB2 signaling
  • PIP3 activates AKT signaling
  • GRB7 events in ERBB2 signaling
  • Downregulation of ERBB2:ERBB3 signaling
  • GRB2 events in ERBB2 signaling
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Sema4D induced cell migration and growth-cone collapse
  • RAF/MAP kinase cascade
  • ERBB2 Regulates Cell Motility
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • ERBB2 Activates PTK6 Signaling
  • Downregulation of ERBB2 signaling
  • TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
  • Constitutive Signaling by Overexpressed ERBB2
  • Drug-mediated inhibition of ERBB2 signaling
  • Signaling by ERBB2 KD Mutants
  • Resistance of ERBB2 KD mutants to trastuzumab
  • Resistance of ERBB2 KD mutants to sapitinib
  • Resistance of ERBB2 KD mutants to tesevatinib
  • Resistance of ERBB2 KD mutants to neratinib
  • Resistance of ERBB2 KD mutants to osimertinib
  • Resistance of ERBB2 KD mutants to afatinib
  • Resistance of ERBB2 KD mutants to AEE788
  • Resistance of ERBB2 KD mutants to lapatinib
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Drug resistance in ERBB2 TMD/JMD mutants
  • Developmental Lineage of Mammary Gland Luminal Epithelial Cells
  • Developmental Lineage of Mammary Gland Myoepithelial Cells
  • Developmental Lineage of Mammary Stem Cells
  • Trastuzumab
  • Lapatinib
  • IGN311
  • Trastuzumab emtansine
  • Varlitinib
  • AV-412
  • Pertuzumab
  • Afatinib
  • Tucatinib
  • Tesevatinib
  • Fostamatinib
  • Brigatinib
  • Margetuximab
  • Zanubrutinib
  • Breast cancer
  • Cervical cancer
  • Cholangiocarcinoma
  • Pancreatic cancer
  • Gastric cancer
  • Ovarian cancer
  • Choriocarcinoma
  • Endometrial Cancer
  • Bladder cancer
Novel ERRFI1 ERBB receptor feedback inhibitor 1
Novel FBXO7 F-box protein 7
  • Neddylation
  • Antigen processing: Ubiquitination & Proteasome degradation
  • Parkinson's disease (PD)
Novel FGF1 fibroblast growth factor 1
  • PI3K Cascade
  • PIP3 activates AKT signaling
  • Signaling by activated point mutants of FGFR1
  • Signaling by activated point mutants of FGFR3
  • FGFR4 ligand binding and activation
  • FGFR1b ligand binding and activation
  • FGFR3b ligand binding and activation
  • FGFR3c ligand binding and activation
  • FGFR1c ligand binding and activation
  • FGFR2c ligand binding and activation
  • FGFR2b ligand binding and activation
  • Activated point mutants of FGFR2
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Phospholipase C-mediated cascade: FGFR1
  • Phospholipase C-mediated cascade; FGFR2
  • Phospholipase C-mediated cascade; FGFR3
  • Phospholipase C-mediated cascade; FGFR4
  • Downstream signaling of activated FGFR1
  • SHC-mediated cascade:FGFR1
  • PI-3K cascade:FGFR1
  • FRS-mediated FGFR1 signaling
  • PI-3K cascade:FGFR2
  • SHC-mediated cascade:FGFR2
  • FRS-mediated FGFR2 signaling
  • SHC-mediated cascade:FGFR3
  • FRS-mediated FGFR3 signaling
  • PI-3K cascade:FGFR3
  • FRS-mediated FGFR4 signaling
  • SHC-mediated cascade:FGFR4
  • PI-3K cascade:FGFR4
  • Negative regulation of FGFR1 signaling
  • Negative regulation of FGFR2 signaling
  • Negative regulation of FGFR3 signaling
  • Negative regulation of FGFR4 signaling
  • Signaling by FGFR2 in disease
  • Signaling by FGFR1 in disease
  • Signaling by FGFR3 in disease
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Signaling by FGFR2 IIIa TM
  • Pentosan polysulfate
  • Amlexanox
  • Heparin
  • Sucrosofate
  • Formic acid
  • O2-Sulfo-Glucuronic Acid
  • N,O6-Disulfo-Glucosamine
  • Naphthalene Trisulfonate
  • Pazopanib
  • 5-aminonaphthalene-2-sulfonic acid
  • Foreskin fibroblast (neonatal)
  • Foreskin keratinocyte (neonatal)
Novel FGF10 fibroblast growth factor 10
  • PI3K Cascade
  • PIP3 activates AKT signaling
  • FGFR1b ligand binding and activation
  • FGFR2b ligand binding and activation
  • Activated point mutants of FGFR2
  • Regulation of gene expression in early pancreatic precursor cells
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Phospholipase C-mediated cascade: FGFR1
  • Phospholipase C-mediated cascade; FGFR2
  • Downstream signaling of activated FGFR1
  • SHC-mediated cascade:FGFR1
  • PI-3K cascade:FGFR1
  • FRS-mediated FGFR1 signaling
  • PI-3K cascade:FGFR2
  • SHC-mediated cascade:FGFR2
  • FRS-mediated FGFR2 signaling
  • Negative regulation of FGFR1 signaling
  • Negative regulation of FGFR2 signaling
  • Signaling by FGFR2 in disease
  • FGFRL1 modulation of FGFR1 signaling
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Developmental Lineage of Multipotent Pancreatic Progenitor Cells
  • Developmental Lineage of Mammary Stem Cells
  • Aplasia of lacrimal and salivary glands
  • Lacrimo-auriculo-dento-digital syndrome (LADD); Levy-Hollister syndrome
Novel FGF17 fibroblast growth factor 17
Novel FGF18 fibroblast growth factor 18
  • PI3K Cascade
  • PIP3 activates AKT signaling
  • Signaling by activated point mutants of FGFR3
  • FGFR4 ligand binding and activation
  • FGFR3b ligand binding and activation
  • FGFR3c ligand binding and activation
  • FGFR2c ligand binding and activation
  • Activated point mutants of FGFR2
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Phospholipase C-mediated cascade; FGFR2
  • Phospholipase C-mediated cascade; FGFR3
  • Phospholipase C-mediated cascade; FGFR4
  • PI-3K cascade:FGFR2
  • SHC-mediated cascade:FGFR2
  • FRS-mediated FGFR2 signaling
  • SHC-mediated cascade:FGFR3
  • FRS-mediated FGFR3 signaling
  • PI-3K cascade:FGFR3
  • FRS-mediated FGFR4 signaling
  • SHC-mediated cascade:FGFR4
  • PI-3K cascade:FGFR4
  • Negative regulation of FGFR2 signaling
  • Negative regulation of FGFR3 signaling
  • Negative regulation of FGFR4 signaling
  • Signaling by FGFR2 in disease
  • Signaling by FGFR3 in disease
  • FGFRL1 modulation of FGFR1 signaling
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
Novel FGF23 fibroblast growth factor 23
  • PI3K Cascade
  • PIP3 activates AKT signaling
  • Signaling by activated point mutants of FGFR1
  • Signaling by activated point mutants of FGFR3
  • FGFR4 ligand binding and activation
  • FGFR3c ligand binding and activation
  • FGFR1c ligand binding and activation
  • FGFR1c and Klotho ligand binding and activation
  • FGFR2c ligand binding and activation
  • Activated point mutants of FGFR2
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
  • Phospholipase C-mediated cascade: FGFR1
  • Phospholipase C-mediated cascade; FGFR2
  • Phospholipase C-mediated cascade; FGFR3
  • Phospholipase C-mediated cascade; FGFR4
  • Downstream signaling of activated FGFR1
  • SHC-mediated cascade:FGFR1
  • PI-3K cascade:FGFR1
  • FRS-mediated FGFR1 signaling
  • PI-3K cascade:FGFR2
  • SHC-mediated cascade:FGFR2
  • FRS-mediated FGFR2 signaling
  • SHC-mediated cascade:FGFR3
  • FRS-mediated FGFR3 signaling
  • PI-3K cascade:FGFR3
  • FRS-mediated FGFR4 signaling
  • SHC-mediated cascade:FGFR4
  • PI-3K cascade:FGFR4
  • Negative regulation of FGFR1 signaling
  • Negative regulation of FGFR2 signaling
  • Negative regulation of FGFR3 signaling
  • Negative regulation of FGFR4 signaling
  • Signaling by FGFR2 in disease
  • Signaling by FGFR1 in disease
  • Signaling by FGFR3 in disease
  • FGFRL1 modulation of FGFR1 signaling
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Post-translational protein phosphorylation
  • Hypophosphatemic rickets; X-Linked dominant hypophosphatemia (XLH); Autosomal dominant hypophosphatemic rickets (ADHR); Autosomal recessive hypophosphatemic rickets (ARHR); Hereditary hypophophatemic rickets with hypercalciuria (HHRH)
Novel FGF3 fibroblast growth factor 3
  • PI3K Cascade
  • PIP3 activates AKT signaling
  • FGFR1b ligand binding and activation
  • FGFR2b ligand binding and activation
  • Activated point mutants of FGFR2
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Phospholipase C-mediated cascade: FGFR1
  • Phospholipase C-mediated cascade; FGFR2
  • Downstream signaling of activated FGFR1
  • SHC-mediated cascade:FGFR1
  • PI-3K cascade:FGFR1
  • FRS-mediated FGFR1 signaling
  • PI-3K cascade:FGFR2
  • SHC-mediated cascade:FGFR2
  • FRS-mediated FGFR2 signaling
  • Negative regulation of FGFR1 signaling
  • Negative regulation of FGFR2 signaling
  • Signaling by FGFR2 in disease
  • FGFRL1 modulation of FGFR1 signaling
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Kaposi's sarcoma
Novel FGF4 fibroblast growth factor 4
  • PI3K Cascade
  • PIP3 activates AKT signaling
  • Signaling by activated point mutants of FGFR1
  • Signaling by activated point mutants of FGFR3
  • FGFR4 ligand binding and activation
  • FGFR3c ligand binding and activation
  • FGFR1c ligand binding and activation
  • FGFR2c ligand binding and activation
  • Activated point mutants of FGFR2
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Phospholipase C-mediated cascade: FGFR1
  • Phospholipase C-mediated cascade; FGFR2
  • Phospholipase C-mediated cascade; FGFR3
  • Phospholipase C-mediated cascade; FGFR4
  • Downstream signaling of activated FGFR1
  • SHC-mediated cascade:FGFR1
  • PI-3K cascade:FGFR1
  • FRS-mediated FGFR1 signaling
  • PI-3K cascade:FGFR2
  • SHC-mediated cascade:FGFR2
  • FRS-mediated FGFR2 signaling
  • SHC-mediated cascade:FGFR3
  • FRS-mediated FGFR3 signaling
  • PI-3K cascade:FGFR3
  • FRS-mediated FGFR4 signaling
  • SHC-mediated cascade:FGFR4
  • PI-3K cascade:FGFR4
  • Negative regulation of FGFR1 signaling
  • Negative regulation of FGFR2 signaling
  • Negative regulation of FGFR3 signaling
  • Negative regulation of FGFR4 signaling
  • Signaling by FGFR2 in disease
  • Signaling by FGFR1 in disease
  • Signaling by FGFR3 in disease
  • FGFRL1 modulation of FGFR1 signaling
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Specification of the neural plate border
  • Developmental Lineage of Multipotent Pancreatic Progenitor Cells
  • Pentosan polysulfate
  • Heparin
  • TP-508

Page 1 out of 6 pages